Charlie Kim

Partner
Full contact info

"Authentic Big Law" – Can we practice law at the very highest levels, while also in a personal, caring and team-focused way that rejects discrimination and self-promotion at the cost of others, and truly reflects the ideals we hold onto so dearly outside of work? We here at Team Cooley answer that question with a resounding "yes!"

Passions

Food

K-Dramas

College Football

Experience

Uber Technologies $8.1 Billion IPO

May 11, 2019

Cooley advised Uber on its $8.1 billion initial public offering of 207,000,000 shares of common stock. Uber, whose securities now trade on the NYSE under the symbol “UBER,” is a mobility platform revolutionizing the personal ridesharing, meal delivery and logistics industries. Partners Dave Peinsipp, Siana Lowrey, Drew Williamson, Charlie Kim and Kristin VanderPas led the Cooley team.

Related contacts

David Peinsipp
Partner, San Francisco
Siana Lowrey
Of Counsel
Drew Williamson
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Arielle H. Friehling
Associate, San Francisco

Related Practices & Industries

Sweetgreen – $418.6 Million IPO

December 6, 2021

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Read more

Related contacts

Nick Hobson
Partner in Charge, Santa Monica, Santa Monica
David Peinsipp
Partner, San Francisco
Siana Lowrey
Of Counsel
Charlie Kim
Partner, San Diego
Julia Boesch
Partner, San Francisco
Mark Cikowski
Associate, Santa Monica
Marjorie Roesser
Associate, San Francisco
Eric Steiner
Paralegal Specialist, San Francisco
Amy Lauren Saldamando
Manager of Capitalization Table Administration, Santa Monica
Kim Merritt
Paralegal Specialist, San Francisco
Barbara Mirza
Partner, Santa Monica
Austin Holt
Partner, Santa Monica
David Navetta
Partner, Colorado
Christian Lee
Associate, San Francisco
Maricel Mojares-Moore
Special Counsel, San Francisco
Matt Kong
Associate, San Francisco
Ross Eberly
Partner, Santa Monica
Eileen Leman
Associate, Los Angeles
Karen Tsai
Special Counsel, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
John Paul Oleksiuk
Partner, New York
Colette Ghazarian
Associate, Los Angeles
Sharon Connaughton
Special Counsel, Washington, DC
Patrick Gibbs
Partner, Palo Alto
Francis Wheeler
Partner, Colorado
Michael Suyat
Senior Paralegal, San Francisco

Related Practices & Industries

CG Oncology Announces Upsized $437 Million IPO

January 29, 2024

Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led the Cooley team advising the underwriters.

Related contacts

Charlie Kim
Partner, San Diego
Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco

Related Practices & Industries

RayzeBio Announces Upsized $357.6 Million IPO

September 19, 2023

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Read more

Related contacts

Carlos Ramirez
Partner, San Diego
Charlie Kim
Partner, San Diego
Marya Postner
Partner, Palo Alto
Terren O'Connor
Associate, San Diego
Valerie Sapozhnikova
Associate, Los Angeles
Jayden Martinez
Associate, Colorado
Michelle Hunt
Associate
Todd Gluth
Partner, San Diego
Tony P. Guan
Associate, Santa Monica
Nathaniel Hearn Jr.
Associate, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Kelly Nelle
Paralegal Specialist, San Diego
Rebecca Ross
Special Counsel, Washington, DC
Jeffrey J. Tolin
Partner, New York
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Structure Therapeutics – $185.3 Million IPO

February 9, 2023

San Francisco – February 9, 2023 Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Andrew Harline
Partner in Charge – Singapore, Singapore
Su Lian Lu
Special Counsel, Santa Monica
Xander Lee
Partner, Santa Monica
Jie Zhang
Partner, Hong Kong
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Carlos Ramirez
Partner, San Diego
Ryan Blair
Partner, San Diego
Joshua Mates
Partner, San Francisco
Mark Ballantyne
Partner, Reston
Nicola Squire
Partner, London
Francis Wheeler
Partner, Colorado
Will Cai
Partner, Hong Kong
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Dani Nazemian
Special Counsel, San Diego
Randy Sabett
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Rebecca Ross
Special Counsel, Washington, DC
Lisa Yuan
Special Counsel, Beijing
Christine Turner
Associate, Colorado
Vince Flynn
Associate, San Diego
Ivy Wang
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Cara Buchicchio
Associate, New York
Megan Drill
Associate, San Diego
Daniel Gillon
Associate, San Diego
Dionne A. Thomas
Associate, San Diego
Cristina Ferruolo
Associate, San Diego
Brian Lau
Associate, Hong Kong
Jessica Wade
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego
Lunga Su
Associate, Shanghai
Christine S. Kim
Associate, San Diego
Andy Zachrich
Associate, San Diego

Related Practices & Industries

View more

Charlie Kim skillfully navigating your capital markets transactions - priceless. Charlie's depth and breadth of knowledge/experience was crucial in the successful execution of our IPO and multiple follow-on offerings which tallied to over $1.2 billion. Internally, we nicknamed Charlie the 'Ironman of Capital Markets'. He and his team were a pleasure to partner with from the pre-planning phase all the way through the end of the process.

Tom Walker, former CFO of Tableau Software

Admissions and credentials

California

New York

Rankings and accolades

Chambers USA: Band 1 for Capital Markets: Debt & Equity – California and Nationwide

The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings

Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award

The Daily Transcript: San Diego Top Attorney

Law360: MVP of the Year – Capital Markets

Thomson Reuters: Super Lawyer – Southern California and San Diego

 

Memberships and affiliations

American Bar Association (ABA)

Council of Korean Americans

New York State Bar Association

San Diego County Bar Association

Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Boundless Bio, Cadence, CARGO, Castlight, Cerus, CG Oncology, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, RayzeBio, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Uber Technologies, Vaxcyte, Ventyx Biosciences, Verenium, Verona, Vical, ViewRay, Viking, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.